Breaking News

Chugai and Galderma Establish Partnership

Form global license agreement for a novel biologic for skin diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Chugai Pharmaceutical and Galderma Pharma have entered into a global license agreement for nemolizumab (CIM331) the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patients. “This agreement highlights the great expectation for nemolizumab which possesses a novel mechanism of action to improve atopic dermatitis by breaking the itch-scratch cycle,” said Tatsuro Kosaka, president and ch...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters